IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.953
AS - Asia 3.357
EU - Europa 2.186
SA - Sud America 498
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 127
OC - Oceania 7
Totale 10.325
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.838
SG - Singapore 1.216
IT - Italia 818
CN - Cina 624
VN - Vietnam 578
BR - Brasile 359
HK - Hong Kong 267
IE - Irlanda 267
BD - Bangladesh 253
SE - Svezia 243
DE - Germania 179
FR - Francia 150
ZA - Sudafrica 123
NL - Olanda 114
IN - India 104
GB - Regno Unito 80
RU - Federazione Russa 72
CA - Canada 57
FI - Finlandia 54
AR - Argentina 49
ID - Indonesia 46
AT - Austria 43
JP - Giappone 35
TR - Turchia 30
IQ - Iraq 29
PH - Filippine 28
KR - Corea 25
ES - Italia 24
CO - Colombia 23
MX - Messico 22
PK - Pakistan 20
PL - Polonia 19
CI - Costa d'Avorio 18
CZ - Repubblica Ceca 18
IR - Iran 18
VE - Venezuela 18
UA - Ucraina 16
BE - Belgio 15
CL - Cile 15
EC - Ecuador 15
TH - Thailandia 14
UZ - Uzbekistan 14
MA - Marocco 13
SA - Arabia Saudita 12
LT - Lituania 11
CR - Costa Rica 9
EG - Egitto 9
GR - Grecia 9
MY - Malesia 9
TN - Tunisia 9
BG - Bulgaria 7
PY - Paraguay 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
LU - Lussemburgo 6
MD - Moldavia 5
PE - Perù 5
BY - Bielorussia 4
JO - Giordania 4
KE - Kenya 4
KZ - Kazakistan 4
SN - Senegal 4
AZ - Azerbaigian 3
BO - Bolivia 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
HU - Ungheria 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
SC - Seychelles 3
AL - Albania 2
BB - Barbados 2
BS - Bahamas 2
DK - Danimarca 2
DZ - Algeria 2
GY - Guiana 2
JM - Giamaica 2
LV - Lettonia 2
PR - Porto Rico 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CG - Congo 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
Totale 10.183
Salva come PNG Salva come JPEG
Città #
Singapore 692
Ashburn 544
San Jose 471
Dallas 425
Chandler 284
Santa Clara 265
Dublin 262
Hong Kong 244
Council Bluffs 184
Ho Chi Minh City 177
Boardman 143
Parma 138
New York 136
Beijing 125
Hanoi 123
Milan 119
Johannesburg 116
Los Angeles 110
Shanghai 90
Munich 84
Lauterbourg 76
Hefei 63
Bologna 61
Chicago 57
Buffalo 51
Rome 46
São Paulo 39
Princeton 38
Vienna 33
Frankfurt am Main 28
Jakarta 28
Verona 27
Haiphong 26
Helsinki 26
Marseille 26
Atlanta 25
Moscow 25
Tokyo 25
Ann Arbor 24
Nuremberg 24
Amsterdam 23
Da Nang 23
Turku 23
Columbus 22
London 22
Des Moines 21
The Dalles 21
Abidjan 18
Reggio Emilia 18
Seattle 18
Seoul 18
Toronto 18
Biên Hòa 17
Chennai 17
Denver 17
Modena 17
Bremen 16
Phoenix 16
Naples 14
Warsaw 14
Istanbul 13
Montreal 13
Orem 13
Rio de Janeiro 13
Figino 12
Florence 12
West Jordan 12
Belo Horizonte 11
Bengaluru 11
Brooklyn 11
Charlotte 11
Houston 11
Pune 11
Tashkent 11
Trento 11
Baghdad 10
Brno 10
Fremont 10
Manchester 10
Poplar 10
Redondo Beach 10
Athens 9
Boston 9
Brasília 9
Brussels 9
Chongqing 9
Hải Dương 9
Lahore 9
Sorbolo 9
Tehran 9
Wilmington 9
Bangkok 8
Düsseldorf 8
Pasadena 8
Bari 7
Cairo 7
Campinas 7
Curitiba 7
Manaus 7
Manila 7
Totale 6.245
Salva come PNG Salva come JPEG
Nome #
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 258
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 249
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 223
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 214
227P Sexual dimorphism in immune profile of early and advanced NSCLC 207
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 206
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 192
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 190
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 189
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 189
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 183
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 183
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 180
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 171
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 170
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 169
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 168
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 165
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 163
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 157
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 154
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 151
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 150
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 149
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 149
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 148
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 144
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 142
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 142
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 139
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 135
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 134
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 131
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 128
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 127
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 125
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 125
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 123
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 122
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 120
Small cell lung cancer: Novel treatments beyond immunotherapy 118
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 118
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 118
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 117
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 115
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 114
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 113
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 108
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 103
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 103
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 103
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 102
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 101
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 100
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 99
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 99
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 98
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 98
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 98
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 98
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 98
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 97
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 97
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 96
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 91
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 88
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 87
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 86
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 82
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 82
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 78
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 75
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 74
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 74
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study 70
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 64
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 60
Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 58
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 55
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 53
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges 35
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study 26
Liquid Biopsy Monitoring in BRAF V600E–Mutated Patients With Non–Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020) 4
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study 3
Effectiveness of carboplatin vs cisplatin in lung cancer chemo-immunotherapy: A systematic review and meta-analysis 3
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study 2
Totale 10.325
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.225
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022263 0 0 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/20252.010 63 125 155 149 163 184 137 93 212 193 163 373
2025/20265.470 429 387 820 459 615 297 480 240 715 446 407 175
2026/2027692 206 296 190 0 0 0 0 0 0 0 0 0
Totale 10.325